Research Article
Volume 3 Issue 2 - 2021
Which Menopausal Symptoms after Adjuvant Endocrine Breast Cancer Therapy are Addressed by Health Care Providers? Medical Records Notes Versus Self-Reported Side-Effects
Aina Johnsson1,2,5*, Kerstin Sjögren Fugl-Meyer2,3, Mojgan Ebrahim4, Johanna Stjärntfelt2 and Anna von Wachenfeldt-Väppling5,6
1Department of Oncology and Pathology, Karolinska Institutet, SE-17177 Stockholm, Sweden
2Department of Neurobiology, Care Science and Society, Karolinska Institutet, Alfred Nobels allé 23, D2, SE-141 83 Huddinge, Sweden
3Function area Social work in health care, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden
4Diagnostic radiology Karolinska University Hospital, SE-14186 Huddinge, Sweden.
5Department of Oncology, Södersjukhuset, Sjukhusbacken 10, SE-11861 Stockholm, Sweden
6Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, SE-118 83 Stockholm, Sweden
*Corresponding Author: Aina Johnsson, Karolinska Institutet, Department of Neurobiology, Care Science and Society, Division of Family Medicine, Fack 23400 SE-141 83 Huddinge, Sweden.
Received: October 25, 2020; Published: January 30, 2021


Objective: This study examines reports from healthcare providers and patients concerning menopausal side-effects associated with adjuvant endocrine breast cancer therapy (AET) after a breast cancer diagnosis.

Methods: This study is based on data from 81 women between 32 - 62 years old with hormone receptor-positive breast cancer. The study consists of: i) a longitudinal medical record cohort study and ii) self-reported data from a questionnaire in the same cohort. The medical record cohort study covered up to five years of data from the start to completion of AET. Two years after completing AET, the women were mailed a questionnaire that addressed the side-effects they had experienced during the therapy.

Results: The reported side-effects in the questionnaire were significantly higher in terms of vaginal dryness (P = 0.0026), genital sexual pain (P < 0.001) and decreased sexual desire (P < 0.001) than in the medical records. With regard to sweating and flushes, the differences between what was reported in the medical records and what the women stated in the questionnaire were not significant.

Conclusion: Communication and counselling about menopause-related side-effects, especially sex-life-related issues, need to be improved and the reasons for this poor communication need to be elucidated.

Keyword: Breast Cancer; Endocrine Side-Effects; Sexuality; Questionnaire


  1. “National Board of Health and Welfare”. Official statistics of Sweden, Statistics – Health and Medical Care, Cancer Incidence in Sweden 2016”. Stockholm (2017).
  2. Kemetli L., et al. “Temporal trends in the use of adjuvant systemic therapy in breast cancer: a population based study in Sweden 1976-2005”. Acta Oncologica 1 (2009): 59-66.
  3. Davies C., et al. “Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial”. Lancet 9869 (2013): 805-816.
  4. Brower V. “Adjuvant trastuzumab improves survival in early breast cancer”. The Lancet Oncology13 (2014): e589.
  5. Burstein HJ., et al. “Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression”. Journal of Clinical Oncology 14 (2016): 1689-1701.
  6. Davies C., et al. “Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials”. Lancet 9793 (2011): 771-784.
  7. Dowsett M., et al. “Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen”. Journal of Clinical Oncology 3 (2010): 509-518.
  8. Baumgart J., et al. “Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer”. Menopause 2 (2013): 162-168.
  9. Buijs C., et al. “The influence of endocrine treatments for breast cancer on health-related quality of life”. Cancer Treatment Reviews7 (2008): 640-655.
  10. Frechette D., et al. “The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study”. Breast Cancer Research and Treatment 1 (2013): 111-117.
  11. Panjari M., et al. “Sexual function after breast cancer”. The Journal of Sexual Medicine 1 (2011): 294-302.
  12. Cobo-Cuenca AI., et al. “Sexual dysfunction in Spanish women with breast cancer”. PloS one8 (2018): e0203151.
  13. Raggio GA., et al. “Prevalence and correlates of sexual morbidity in long-term breast cancer survivors”. Psychology and Health6 (2014): 632-650.
  14. Safarinejad MR., et al. “Quality of life and sexual functioning in young women with early-stage breast cancer 1 year after lumpectomy”. Psychooncology 6 (2013): 1242-1248.
  15. Ussher JM., et al. “Changes to sexual well-being and intimacy after breast cancer”. Cancer Nursing 6 (2012): 456-465.
  16. Wang F., et al. “A neglected issue on sexual well-being following breast cancer diagnosis and treatment among Chinese women”. Plos One9 (2013): e74473.
  17. Andrzejczak E., et al. “Partner relationships after mastectomy in women not offered breast reconstruction”. Psycho-Oncology7 (2013): 1653-1657.
  18. Langlet E. “Perorala antihormonella läkemedel för adjuvant terapi vid bröstcancer. En enkätundersökning av tilläggsbehandling med antihormonella tabletter bland BCF Amazonas medlemmar. Oral antihormonal drugs for adjuvant therapy in breast cancer. A survey of supplementary therapy with anti-hormonal drugs among BCF Amazon Members”. Retrieved from Stockholm (2015).
  19. Leung J., et al. “Social support and health-related quality of life in women with breast cancer: a longitudinal study”. Psycho-Oncology9 (2014): 1014-1020.
  20. Skördåker A., et al. “Short- And Long-Term Effects of Breast Cancer Diagnosis and Adjuvant Endocrine Treatment on Life Satisfaction”. American Research Journal of Nursing3 (2015): 13-21.
  21. Garreau JR., et al. “Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective”. The American Journal of Surgery 4 (2006): 496-498.
  22. Guth U., et al. “Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?” Breast Cancer Research and Treatment 3 (2011): 799-807.
  23. Den Ouden MEM., et al. “Intimacy and sexuality in women with breast cancer: professional guidance needed”. Breast Cancer3 (2019): 326-332.
  24. Halley MC., et al. “Beyond barriers: fundamental 'disconnects' underlying the treatment of breast cancer patients' sexual health”. Culture, Health and Sexuality 9 (2014): 1169-1180.
  25. Male DA., et al. “Sexual identity after breast cancer: sexuality, body image, and relationship repercussions”. Current Opinion in Supportive and Palliative Care 1 (2016): 66-74.
  26. Taylor S., et al. “Breast Cancer, Sexuality, and Intimacy: Addressing the Unmet Need”. The Breast Journal 4 (2016): 478-479.
  27. Hirschberg AL., et al. “Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial”. Menopause5 (2020): 526-534.
  28. Gianotten WL. “Cancer and sexuality”. In P. S. Kirana, F. Tripodi, Y. Reisman, and H. Porst (Editions.)”. The EFS and ESSM Syllabus of Clinical Sexology (2013): 928-947.
  29. Rasmusson EM., et al. “Did they think I would understand all that on my own?' A questionnaire study about sexuality with Swedish cancer patients”. European Journal of Cancer Care 3 (2013): 361-369.
  30. Dyer K and Das Nair R. “Why don't healthcare professionals talk about sex? A systematic review of recent qualitative studies conducted in the United kingdom”. The Journal of Sexual Medicine 11 (2013): 2658-2670.
Citation: Aina Johnsson., et al. “Which Menopausal Symptoms after Adjuvant Endocrine Breast Cancer Therapy are Addressed by Health Care Providers? Medical Records Notes Versus Self-Reported Side-Effects". EC Nursing and Healthcare 3.2 (2021): 05-11.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

May Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the May issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before May 25, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.